ClinicalTrials.gg
Active, not recruitingNCT05061134MONETTEUpdated Jul 31, 2025Results posted

A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition

A Phase 2 interventional study of Ceralasertib and Durvalumab in Melanoma, sponsored by AstraZeneca. Active, not recruiting at 66 sites in 11 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2025-07-31.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
194
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Melanoma by AstraZeneca — 2 open to participants now, 3 under way, none of them phase 3. Melanoma · AstraZeneca.

Enrollment
5th of 19
194 · median 85
Started
2022
the only one that year
Phase 2
7 of 20
none open now
Registered
18th of 20
by date

Among the 20 studies in Melanoma by AstraZeneca, this one is the 5th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2022, is one of 7 in phase 2, and was the 18th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.

Browse Melanoma studies →

Open to participants now

2 of the 20 studies in Melanoma by AstraZeneca are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Melanoma by AstraZeneca, or all of them as a file.
02

Study summary

Main study: This is an open-label, phase 2 study that aims to evaluate the efficacy and safety/tolerability of ceralasertib, when administered as monotherapy and in combination with durvalumab in participants with unresectable or advanced melanoma and primary or secondary resistance to PD-(L)1 inhibition.

Read the detailed description

Biopsy sub-study: This is an open-label, non-randomised, sub-study planned in participants suitable for 3 mandatory biopsies. Serial tumour biopsies are mandated in participants recruited into the sub-study and will be taken at baseline during the screening period, during treatment with ceralasertib monotherapy and during the off-treatment period of ceralasertib monotherapy.

03

Conditions studied

  • Melanoma

Browse trials for

Keywords

  • Unresectable or Advanced Melanoma
  • Efficacy
  • Safety
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have a or cytologically confirmed diagnosis of unresectable or melanoma of cutaneous, acral or mucosal subtype
  • Availability of an and a fresh tumour biopsy taken at screening
  • Patient must have received at least 1 prior immunotherapy (anti-PD-(L)1 ± [Cytotoxic T-lymphocyte-associated protein 4]) for a minimum of 6 weeks and no more than 2 prior regimens in the metastatic setting. Patients must have confirmed progression during treatment with a PD-(L)1 inhibitor +/- a CTLA-4 inhibitor.
  • The interval between the last dose of anti-PD-(L)1, BRAF/MEK (B-Rapidly Accelerated Fibrosarcoma gene/mitogen-activated protein kinase gene) inhibitor and the first dose of the study regimen must be a minimum of 14 days
  • by 1.1.
  • Patients must have a ≥3 months from proposed first dose date.
  • Biopsy Sub-study: Consent to the provision of 3 mandatory tumour biopsies.

Exclusion criteria

Exclusion Criteria:

  • Patients must not have experienced a toxicity that led to permanent discontinuation of prior (CPI) treatment.
  • History of another primary except for malignancy treated with curative intent with no known active disease ≥ 3 years before the first dose of study treatment
  • Uveal melanoma
  • Must not have experienced a Grade ≥ 3 immune-related AE or an immune-related neurologic or ocular AE of any grade while receiving prior immunotherapy
  • History of symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, which is symptomatic or requires treatment ( Grade 3), symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia. Patients with atrial fibrillation controlled by medication or arrhythmias controlled by pacemakers may be permitted upon discussion with the study clinical lead.
  • History of organ transplant that requires use of medications
  • Inadequate bone marrow and impaired hepatic or renal function
  • Known active infection requiring systemic therapy, active hepatitis infection, positive virus antibody, virus (HBV) surface antigen or HBV core antibody (anti-HBc), at screening
  • Patients with confirmed COVID-19 infection by polymearse chain reaction test who have not made a full recovery.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
194 participants (actual)

Study arms

  • Experimental
    Main study: Ceralasertib + Durvalumab

    Participants will receive ceralasertib on Days 1 to 7 plus durvalumab Day 8, once in 28 days (Q28D), until progressive disease, unacceptable toxicity, withdrawal of consent, or if a study treatment discontinuation criterion is met.

    Drug: Ceralasertib · Biological: Durvalumab

  • Experimental
    Main study: Ceralasertib

    Participants will receive ceralasertib on Days 1 to 7, Q28D, until progressive disease, unacceptable toxicity, withdrawal of consent, or if a study treatment discontinuation criterion is met.

    Drug: Ceralasertib

  • Experimental
    Biopsy Sub-study: Ceralasertib + Durvalumab

    From Cycle 1, participants will receive combination of ceralasertib twice daily (BD) Days 1 to 7 plus durvalumab Day 8, Q28D, until progressive disease, unacceptable toxicity, withdrawal of consent, or a study treatment discontinuation criterion is met.

    Drug: Ceralasertib · Biological: Durvalumab

  • Experimental
    Biopsy study: Ceralasertib

    During Cycle 0, participants will receive ceralasertib on Days 1 to 7, followed by an off-treatment period between Days 8 to 28.

    Drug: Ceralasertib

Interventions

  • Ceralasertib (240 mg) will be administered orally twice daily.

  • BiologicalDurvalumab

    Durvalumab (1500 mg) will be administered intravenously once every 28 days for participants who weight above \> 30 kgs. For participants who weigh below ≤ 30 kgs, weight-based dosing equivalent to 20 mg/kg of durvalumab will be administered.

06

What researchers measure

Primary outcomes

  1. Main Study: Objective Response Rate (ORR)

    ORR was defined as the proportion of participants who had a complete response (CR) or partial response (PR) prior to any evidence of progression (as defined by Response Evaluation Criteria in Solid Tumours \[RECIST\] 1.1) that is confirmed at least 4 weeks later. As per planned in protocol, this outcome measure was assessed only for main study.

    Time frame: Cycle 1 Day 1 (Each Cycle is 28 days) until objective disease progression or the last evaluable assessment in the absence of progression, or data cut-off (1 year 8 months)

  2. Biopsy Study: Change From Baseline in CD8+ T-cells Tumour Infiltration-area in the Center Tumor Region

    Changes in CD8+ T-cell infiltration of tumours induced by ceralasertib monotherapy was assessed in baseline, on-treatment and off-treatment tumour biopsies As per planned in protocol, this outcome measure was assessed only for biopsy study.

    Time frame: Baseline, On-treatment (Cycle 0 Day 7), and Off-treatment (Cycle 0 Day 15-28) (each cycle is 28 days)

  3. Biopsy Study: Change From Baseline in CD8+ T-cells Tumour Infiltration-area in the Invasive Margin Region

    Changes in CD8+ T-cell infiltration of tumours induced by ceralasertib monotherapy was assessed in baseline and off-treatment tumour biopsies As per planned in protocol, this outcome measure was assessed only for biopsy study.

    Time frame: Baseline, Off-treatment (Cycle 0 Day 15-28) (each cycle is 28 days)

  4. Biopsy Study: Change From Baseline in CD8+ T-cells Tumour Infiltration-density in the Center Tumor Region

    Changes in CD8+ T-cell infiltration of tumours induced by ceralasertib monotherapy was assessed in baseline, on-treatment and off-treatment tumour biopsies As per planned in protocol, this outcome measure was assessed only for biopsy study.

    Time frame: Baseline, On-treatment (Cycle 0 Day 7), and Off-treatment (Cycle 0 Day 15-28) (each cycle is 28 days)

  5. Biopsy Study: Change From Baseline in CD8+ T-cells Tumour Infiltration-density in the Invasive Margin Region

    Changes in CD8+ T-cell infiltration of tumours induced by ceralasertib monotherapy was assessed in baseline and off-treatment tumour biopsies As per planned in protocol, this outcome measure was assessed only for biopsy study.

    Time frame: Baseline, and Off-treatment (Cycle 0 Day 15-28) (each cycle is 28 days)

Secondary outcomes

  1. Main Study and Biopsy Study: Duration of Response (DOR)

    DOR was defined as the time from the date of first documented confirmed response until date of documented progression per RECIST 1.1 or death due to any cause. For main study BICR data is presented, and for Biopsy sub study, investigator assessment data has been presented.

    Time frame: Cycle 1 Day 1 (each cycle is 28 days) until date of documented progression or data cut-off (2 years), whichever occurred first

  2. Main Study and Biopsy Study: Time to Response

    Time to response was defined as the time from randomization until the date of first documented objective response, which is subsequently confirmed per RECIST 1.1. For main study blinded independent central review (BICR) data is presented, and for Biopsy sub study, investigator assessment data has been presented.

    Time frame: Cycle 1 Day 1 (each cycle is 28 days) until date of documented progression or data cut-off (2 years), whichever occurred first

  3. Main Study and Biopsy Study: Percentage Change From Baseline in Tumour Size

    Percentage change from baseline in target lesion (TL) tumour size was assessed. Tumour size is the sum of the longest diameters of the target lesions. The percentage change from baseline in TL tumour size at post-baseline assessment is obtained for each participants taking the difference between the sum of the TLs at post baseline assessment and the sum of the TLs at baseline divided by the sum of the TLs at baseline times 100. Percentage change from baseline at 16 weeks for main study and 20 weeks for biopsy study in sum of target lesions has been presented. For main study, BICR data is presented, and for Biopsy sub study, investigator assessment data has been presented.

    Time frame: Main Study: at 16 weeks; Biopsy study: at 20 weeks

  4. Main Study and Biopsy Study: Progression Free Survival (PFS)

    PFS was defined as time from randomization until progression per RECIST 1.1 or death due to any cause. For main study BICR data is presented, and for Biopsy sub study, investigator assessment data has been presented.

    Time frame: Cycle 1 Day 1 (each cycle is 28 days) until date of documented progression or data cut-off (2 years), whichever occurred first

  5. Main Study and Biopsy Study: Overall Survival (OS)

    OS was defined as time from date of randomization until the date of death due to any cause.

    Time frame: Cycle 1 Day 1 (each cycle is 28 days) until date of documented progression or data cut-off (2 years), whichever occurred first

  6. Main Study: Plasma Concentration of Ceralasertib

    Pharmacokinetic (PK) of ceralasertib alone and when in combination with durvalumab was assessed.

    Time frame: From Cycle 1 to Cycle 4: Day 7 and Day 8 of each cycle (each cycle is 28 days); 90 days follow-up

  7. Main Study and Biopsy Study: Number of Participants With Adverse Events (AEs)

    The safety and tolerability of ceralasertib monotherapy and ceralasertib plus durvalumab in participants with unresectable or advanced melanoma and primary or secondary resistance to a programmed death ligand 1 (PD-\[L\] 1) inhibitor was assessed. The grading scales found in the revised National Cancer Institute CTCAE latest version was utilized for all events with an assigned CTCAE grading. Grade refers to the severity of the AE. The CTCAE displays Grades 1 through 5 where Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL. Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL; Grade 4: Life-threatening, urgent intervention required; Grade 5: Death related to AE.

    Time frame: From screening (Day -28 to -1) until Safety follow-up (30 days after last dose of Ceralasertib monotherapy or 90 days after last dose of Ceralasertib+Durvalumab combination) or data cut-off (2 years), whichever occurred first

  8. Biopsy Study: Number of Participants With Presence of PD-L1 Overtime

    Pre-treatment presence and/or on-treatment and/or off-treatment changes in PD-L1 was assessed to collect tumour tissue samples, or utilise residual samples, for the analysis of tumoural biomarkers that change following treatment with ceralasertib was assessed. As per planned in protocol, this outcome measure was assessed only for biopsy study. The number of patients with PD-L1 expression \<1% and \>= 1% has been presented.

    Time frame: Baseline, On-treatment (Cycle 0 Day 7); Off-treatment (Cycle 0 Day 15-28) (each cycle is 28 days)

  9. Biopsy Study: Number of Participants With Presence of pRAD50

    Pre-treatment presence and/or on-treatment and/or off-treatment changes in pRAD50 was assessed to collect tumour tissue samples, or utilise residual samples, for the analysis of tumoural biomarkers that change following treatment with ceralasertib was assessed. As per planned in protocol, this outcome measure was assessed only for biopsy study.

    Time frame: On-treatment (Cycle 0 Day 7); Off-treatment (Cycle 0 Day 15-28) (each cycle is 28 days)

  10. Biopsy Study: Change From Baseline in Proliferation (Using Ki67+ Marker) of Carcinoma and/or Immune Cells (Including CD8+ T Cells) - Cell Density in Center Tumour Region

    Changes in the proliferation of carcinoma and/or immune cells within tumours induced by ceralasertib monotherapy was assessed. As per planned in protocol, this outcome measure was assessed only for biopsy study.

    Time frame: Baseline, On-treatment (Cycle 0 Day 7); Off-treatment (Cycle 0 Day 15-28) (each cycle is 28 days)

  11. Biopsy Study: Change From Baseline in Proliferation (Using Ki67+ Marker) of Carcinoma and/or Immune Cells (Including CD8+ T Cells) - Cell Density in Invasive Margin Region

    Changes in the proliferation of carcinoma and/or immune cells within tumours induced by ceralasertib monotherapy was assessed. As per planned in protocol, this outcome measure was assessed only for biopsy study.

    Time frame: Baseline, On-treatment (Cycle 0 Day 7); Off-treatment (Cycle 0 Day 15-28) (each cycle is 28 days)

  12. Biopsy Study: Change From Baseline in Proliferation (Using Ki67+ Marker) of Carcinoma and/or Immune Cells (Including CD8+ T Cells) - Area in Centre Tumour Region

    Changes in the proliferation of carcinoma and/or immune cells within tumours induced by ceralasertib monotherapy was assessed. As per planned in protocol, this outcome measure was assessed only for biopsy study.

    Time frame: Baseline, On-treatment (Cycle 0 Day 7); Off-treatment (Cycle 0 Day 15-28) (each cycle is 28 days)

  13. Biopsy Study: Change From Baseline in Proliferation (Using Ki67+ Marker) of Carcinoma and/or Immune Cells (Including CD8+ T Cells) - Area in Invasive Margin Region

    Changes in the proliferation of carcinoma and/or immune cells within tumours induced by ceralasertib monotherapy was assessed. As per planned in protocol, this outcome measure was assessed only for biopsy study.

    Time frame: Baseline, On-treatment (Cycle 0 Day 7); Off-treatment (Cycle 0 Day 15-28) (each cycle is 28 days)

07

Results

Posted May 21, 2025

Participant flow

This study was conducted between 11 Aug 2022 (first participants enrolled) to 12 Apr 2024 (primary completion date). The study was conducted in 11 countries.

Participant flow — Overall Study
MilestoneMain Study: Ceralasertib + DurvalumabMain Study: Ceralasertib MonotherapyBiopsy Study: Ceralasertib + Durvalumab
Started1005143
Completed000
Not completed1005143
Withdrew: Patients ongoing in the study at data cut-off (dco) of 12-april-20241936
Withdrew: Subject not treated002
Withdrew: Other009
Withdrew: Withdrawal by subject985
Withdrew: Study terminated by sponsor22147
Withdrew: Progressive disease120
Withdrew: Patient is on survival follow up beyond dco100
Withdrew: Lost to follow-up100
Withdrew: Physician decision110
Withdrew: Disease progression100
Withdrew: Death432314
Withdrew: Database lock200

Outcome measures

PrimaryMain Study: Objective Response Rate (ORR)

ORR was defined as the proportion of participants who had a complete response (CR) or partial response (PR) prior to any evidence of progression (as defined by Response Evaluation Criteria in Solid Tumours \[RECIST\] 1.1) that is confirmed at least 4 weeks later. As per planned in protocol, this outcome measure was assessed only for main study.

Time frame:
Cycle 1 Day 1 (Each Cycle is 28 days) until objective disease progression or the last evaluable assessment in the absence of progression, or data cut-off (1 year 8 months)
Reported as:
Number · Percentage of participants
Main Study: Objective Response Rate (ORR)
Percentage of participantsMain Study: Ceralasertib + DurvalumabMain Study: Ceralasertib Monotherapy
Main Study: Objective Response Rate (ORR)9.3 (4.3 to 16.9)5.8 (1.2 to 15.9)
PrimaryBiopsy Study: Change From Baseline in CD8+ T-cells Tumour Infiltration-area in the Center Tumor Region

Changes in CD8+ T-cell infiltration of tumours induced by ceralasertib monotherapy was assessed in baseline, on-treatment and off-treatment tumour biopsies As per planned in protocol, this outcome measure was assessed only for biopsy study.

Time frame:
Baseline, On-treatment (Cycle 0 Day 7), and Off-treatment (Cycle 0 Day 15-28) (each cycle is 28 days)
Reported as:
Mean · Percent change
Biopsy Study: Change From Baseline in CD8+ T-cells Tumour Infiltration-area in the Center Tumor Region
Percent changeBiopsy Study: Ceralasertib + Durvalumab
On-treatment-0.976 ± 2.920
Off-treatment-0.451 ± 1.357
SecondaryMain Study and Biopsy Study: Duration of Response (DOR)

DOR was defined as the time from the date of first documented confirmed response until date of documented progression per RECIST 1.1 or death due to any cause. For main study BICR data is presented, and for Biopsy sub study, investigator assessment data has been presented.

Time frame:
Cycle 1 Day 1 (each cycle is 28 days) until date of documented progression or data cut-off (2 years), whichever occurred first
Reported as:
Median · Months
Main Study and Biopsy Study: Duration of Response (DOR)
MonthsMain Study: Ceralasertib + DurvalumabMain Study: Ceralasertib MonotherapyBiopsy Study: Ceralasertib + Durvalumab
Main Study and Biopsy Study: Duration of Response (DOR)NA (7.5 to NA)NA (5.6 to NA)NA (5.8 to NA)
SecondaryMain Study and Biopsy Study: Time to Response

Time to response was defined as the time from randomization until the date of first documented objective response, which is subsequently confirmed per RECIST 1.1. For main study blinded independent central review (BICR) data is presented, and for Biopsy sub study, investigator assessment data has been presented.

Time frame:
Cycle 1 Day 1 (each cycle is 28 days) until date of documented progression or data cut-off (2 years), whichever occurred first
Reported as:
Median · Months
Main Study and Biopsy Study: Time to Response
MonthsMain Study: Ceralasertib + DurvalumabMain Study: Ceralasertib MonotherapyBiopsy Study: Ceralasertib + Durvalumab
Main Study and Biopsy Study: Time to Response3.5 (1.7 to 5.6)3.6 (2.4 to NA)3.7 (2.7 to NA)
SecondaryMain Study and Biopsy Study: Percentage Change From Baseline in Tumour Size

Percentage change from baseline in target lesion (TL) tumour size was assessed. Tumour size is the sum of the longest diameters of the target lesions. The percentage change from baseline in TL tumour size at post-baseline assessment is obtained for each participants taking the difference between the sum of the TLs at post baseline assessment and the sum of the TLs at baseline divided by the sum of the TLs at baseline times 100. Percentage change from baseline at 16 weeks for main study and 20 weeks for biopsy study in sum of target lesions has been presented. For main study, BICR data is presented, and for Biopsy sub study, investigator assessment data has been presented.

Time frame:
Main Study: at 16 weeks; Biopsy study: at 20 weeks
Reported as:
Mean · Percentage change from baseline
Main Study and Biopsy Study: Percentage Change From Baseline in Tumour Size
Percentage change from baselineMain Study: Ceralasertib + DurvalumabMain Study: Ceralasertib MonotherapyBiopsy Study: Ceralasertib + Durvalumab
Main Study and Biopsy Study: Percentage Change From Baseline in Tumour Size15.80 ± 38.1411.25 ± 33.9917.93 ± 38.46
SecondaryMain Study and Biopsy Study: Progression Free Survival (PFS)

PFS was defined as time from randomization until progression per RECIST 1.1 or death due to any cause. For main study BICR data is presented, and for Biopsy sub study, investigator assessment data has been presented.

Time frame:
Cycle 1 Day 1 (each cycle is 28 days) until date of documented progression or data cut-off (2 years), whichever occurred first
Reported as:
Median · Months
Main Study and Biopsy Study: Progression Free Survival (PFS)
MonthsMain Study: Ceralasertib + DurvalumabMain Study: Ceralasertib MonotherapyBiopsy Study: Ceralasertib + Durvalumab
Main Study and Biopsy Study: Progression Free Survival (PFS)2.00 (1.91 to 3.52)1.94 (1.91 to 3.06)2.83 (2.76 to 4.47)
SecondaryMain Study and Biopsy Study: Overall Survival (OS)

OS was defined as time from date of randomization until the date of death due to any cause.

Time frame:
Cycle 1 Day 1 (each cycle is 28 days) until date of documented progression or data cut-off (2 years), whichever occurred first
Reported as:
Median · Months
Main Study and Biopsy Study: Overall Survival (OS)
MonthsMain Study: Ceralasertib + DurvalumabMain Study: Ceralasertib MonotherapyBiopsy Study: Ceralasertib + Durvalumab
Main Study and Biopsy Study: Overall Survival (OS)16.00 (10.48 to NA)12.32 (9.46 to NA)NA (10.18 to NA)
SecondaryMain Study: Plasma Concentration of Ceralasertib

Pharmacokinetic (PK) of ceralasertib alone and when in combination with durvalumab was assessed.

Time frame:
From Cycle 1 to Cycle 4: Day 7 and Day 8 of each cycle (each cycle is 28 days); 90 days follow-up
Reported as:
Geometric mean · Nanograms per milliliter (ng/mL)
Main Study: Plasma Concentration of Ceralasertib
Nanograms per milliliter (ng/mL)Main Study: Ceralasertib + DurvalumabMain Study: Ceralasertib Monotherapy
Cycle 1 Day 7: pre-dose4621 ± 68.344789 ± 52.03
Cycle 1 Day 7: 1 hour post-dose8304 ± 44.698010 ± 53.84
Cycle 1 Day 8: pre-dose78.10 ± 43.66—
Cycle 1 Day 8: 1 hour post-dose379600 ± 23.05—
Cycle 2 Day 7: pre-dose4487 ± 70.464101 ± 40.53
Cycle 2 Day 7: 1 hour post-dose7735 ± 53.097984 ± 45.39
Cycle 2 Day 8: pre-dose67170 ± 47.38—
Cycle 2 Day 8: 1 hour post-dose425900 ± 36.73—
Cycle 3 Day 7: pre-dose4269 ± 44.724045 ± 51.17
Cycle 3 Day 7: 1 hour post-dose7072 ± 41.817799 ± 41.76
Cycle 3 Day 8: pre-dose105100 ± 50.26—
Cycle 3 Day 8: 1 hour post-dose460800 ± 26.48—
Cycle 4 Day 7: pre-dose—NA ± NA
Cycle 4 Day 7: 1 hour post-dose—7273 ± 33.82
90 Days Follow-up23830 ± 79.06—
SecondaryMain Study and Biopsy Study: Number of Participants With Adverse Events (AEs)

The safety and tolerability of ceralasertib monotherapy and ceralasertib plus durvalumab in participants with unresectable or advanced melanoma and primary or secondary resistance to a programmed death ligand 1 (PD-\[L\] 1) inhibitor was assessed. The grading scales found in the revised National Cancer Institute CTCAE latest version was utilized for all events with an assigned CTCAE grading. Grade refers to the severity of the AE. The CTCAE displays Grades 1 through 5 where Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL. Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL; Grade 4: Life-threatening, urgent intervention required; Grade 5: Death related to AE.

Time frame:
From screening (Day -28 to -1) until Safety follow-up (30 days after last dose of Ceralasertib monotherapy or 90 days after last dose of Ceralasertib+Durvalumab combination) or data cut-off (2 years), whichever occurred first
Reported as:
Count of participants · Participants
Main Study and Biopsy Study: Number of Participants With Adverse Events (AEs)
ParticipantsMain Study: Ceralasertib + DurvalumabMain Study: Ceralasertib MonotherapyBiopsy Study: Ceralasertib + Durvalumab
Any AE924539
Any AE possibly related to treatment743629
Any AE of >= CTCAE grade 3341613
Any AE of >= CTCAE grade 3, possibly related to treatment1794
Any SAE1959
Any SAE possibly related to treatment320
Any SAE of >= CTCAE grade 31639
Any SAE of >= CTCAE grade 3, possibly related to treatment300
Any SAE with outcome death001
Any SAE with outcome death, possibly related to treatment000
Any AE leading to discontinuation of treatment111
Any AE leading to discontinuation of treatment, possibly related to treatment111
Any AE leading to drug interruption of treatment838
Any AE leading to dose reduction of treatment1063
Any AE leading to dose modification of treatment1489
Any SAE leading to discontinuation of treatment000
Any SAE leading to discontinuation of treatment, possibly related to treatment000
Any SAE leading to drug interruption of treatment514
Any SAE leading to dose reduction of treatment200
Any SAE leading to dose modification of treatment514
Any AE of >= CTCAE grade 3, possibly related to Ceralasertib1694
Any AE of >= CTCAE grade 3, possibly related to Durvalumab5—1
Any SAE possibly related to Ceralasertib320
Any SAE possibly related to Durvalumab1—0
Any SAE of >= CTCAE grade 3, possibly related to Ceralasertib300
Any SAE of >= CTCAE grade 3, possibly related to Durvalumab1—0
Any SAE with outcome death, possibly related to Ceralasertib000
Any SAE with outcome death, possibly related to Durvalumab0—0
Any AE leading to discontinuation of Ceralasertib111
Any AE leading to discontinuation of Durvalumab0—1
Any AE leading to discontinuation of Ceralasertib, possibly related to Ceralasertib111
Any AE leading to discontinuation of Durvalumab, possibly related to Durvalumab0—1
Any AE leading to drug interruption of Ceralasertib638
Any AE leading to drug interruption of Durvalumab5—2
Any AE leading to dose reduction of Ceralasertib1063
Any AE leading to dose reduction of Durvalumab0—0
Any AE leading to dose modification of Ceralasertib1389
Any AE leading to dose modification of Durvalumab5—2
Any SAE leading to discontinuation of Ceralasertib000
Any SAE leading to discontinuation of Durvalumab0—0
Any SAE leading to discontinuation of Ceralasertib, possibly related to Ceralasertib000
Any SAE leading to discontinuation of Durvalumab, possibly related to Durvalumab0—0
Any SAE leading to drug interruption of Ceralasertib414
Any SAE leading to drug interruption of Durvalumab3—1
Any SAE leading to dose reduction of Ceralasertib200
Any SAE leading to dose reduction of Durvalumab0—0
Any SAE leading to dose modification of Ceralasertib414
Any SAE leading to dose modification of Durvalumab3—1
SecondaryBiopsy Study: Number of Participants With Presence of PD-L1 Overtime

Pre-treatment presence and/or on-treatment and/or off-treatment changes in PD-L1 was assessed to collect tumour tissue samples, or utilise residual samples, for the analysis of tumoural biomarkers that change following treatment with ceralasertib was assessed. As per planned in protocol, this outcome measure was assessed only for biopsy study. The number of patients with PD-L1 expression \<1% and \>= 1% has been presented.

Time frame:
Baseline, On-treatment (Cycle 0 Day 7); Off-treatment (Cycle 0 Day 15-28) (each cycle is 28 days)
Reported as:
Count of participants · Participants
Biopsy Study: Number of Participants With Presence of PD-L1 Overtime
ParticipantsBiopsy Study: Ceralasertib + Durvalumab
Tumor Positive Membrane score: Baseline: <1% PD-L1 expression22
Tumor Positive Membrane score: Baseline: >=1% PD-L1 expression8
Tumor Positive Membrane score: On-treatment (Cycle 0 Day 7): <1% PD-L1 expression14
Tumor Positive Membrane score: On-treatment (Cycle 0 Day 7): >=1% PD-L1 expression6
Tumor Positive Membrane score: Off-treatment (Cycle 0 Day 15-28): <1% PD-L1 expression17
Tumor Positive Membrane score: Off-treatment (Cycle 0 Day 15-28): >=1% PD-L1 expression8
Tumor Positive Membrane score: Off-treatment (Cycle 0 Day 15-28): unknown1
Tumor Area Positivity score: Baseline:<1% PD-L1 expression12
Tumor Area Positivity score: Baseline: >=1% PD-L1 expression18
Tumor Area Positivity score: On-treatment (Cycle 0 Day 7): <1% PD-L1 expression10
Tumor Area Positivity score: On-treatment (Cycle 0 Day 7): >=1% PD-L1 expression10
Tumor Area Positivity score: Off-treatment (Cycle 0 Day 15-28): <1% PD-L1 expression9
Tumor Area Positivity score: Off-treatment (Cycle 0 Day 15-28): >=1% PD-L1 expression16
Tumor Area Positivity score: Off-treatment (Cycle 0 Day 15-28): unknown1
SecondaryBiopsy Study: Number of Participants With Presence of pRAD50

Pre-treatment presence and/or on-treatment and/or off-treatment changes in pRAD50 was assessed to collect tumour tissue samples, or utilise residual samples, for the analysis of tumoural biomarkers that change following treatment with ceralasertib was assessed. As per planned in protocol, this outcome measure was assessed only for biopsy study.

Time frame:
On-treatment (Cycle 0 Day 7); Off-treatment (Cycle 0 Day 15-28) (each cycle is 28 days)
Reported as:
Count of participants · Participants
Biopsy Study: Number of Participants With Presence of pRAD50
ParticipantsBiopsy Study: Ceralasertib + Durvalumab
Baseline29
On-treatment (Cycle 0 Day 7)18
Off-treatment (Cycle 0 Day 15-28)25
SecondaryBiopsy Study: Change From Baseline in Proliferation (Using Ki67+ Marker) of Carcinoma and/or Immune Cells (Including CD8+ T Cells) - Cell Density in Center Tumour Region

Changes in the proliferation of carcinoma and/or immune cells within tumours induced by ceralasertib monotherapy was assessed. As per planned in protocol, this outcome measure was assessed only for biopsy study.

Time frame:
Baseline, On-treatment (Cycle 0 Day 7); Off-treatment (Cycle 0 Day 15-28) (each cycle is 28 days)
Reported as:
Mean · Change in cells per mm2
Biopsy Study: Change From Baseline in Proliferation (Using Ki67+ Marker) of Carcinoma and/or Immune Cells (Including CD8+ T Cells) - Cell Density in Center Tumour Region
Change in cells per mm2Biopsy Study: Ceralasertib + Durvalumab
CD8+ IHC: On-treatment (Cycle 0 Day 7)-183.589 ± 740.398
CD8+ IHC: Off-treatment (Cycle 0 Day 15-28)-85.259 ± 396.091
Ki67+ IHC: On-treatment (Cycle 0 Day 7)-355.399 ± 461.152
Ki67+ IHC: Off-treatment (Cycle 0 Day 15-28)47.656 ± 1041.627
PrimaryBiopsy Study: Change From Baseline in CD8+ T-cells Tumour Infiltration-area in the Invasive Margin Region

Changes in CD8+ T-cell infiltration of tumours induced by ceralasertib monotherapy was assessed in baseline and off-treatment tumour biopsies As per planned in protocol, this outcome measure was assessed only for biopsy study.

Time frame:
Baseline, Off-treatment (Cycle 0 Day 15-28) (each cycle is 28 days)
Reported as:
Median · Percent change
Biopsy Study: Change From Baseline in CD8+ T-cells Tumour Infiltration-area in the Invasive Margin Region
Percent changeBiopsy Study: Ceralasertib + Durvalumab
Biopsy Study: Change From Baseline in CD8+ T-cells Tumour Infiltration-area in the Invasive Margin RegionNA (-0.73 to -0.73)
PrimaryBiopsy Study: Change From Baseline in CD8+ T-cells Tumour Infiltration-density in the Center Tumor Region

Changes in CD8+ T-cell infiltration of tumours induced by ceralasertib monotherapy was assessed in baseline, on-treatment and off-treatment tumour biopsies As per planned in protocol, this outcome measure was assessed only for biopsy study.

Time frame:
Baseline, On-treatment (Cycle 0 Day 7), and Off-treatment (Cycle 0 Day 15-28) (each cycle is 28 days)
Reported as:
Mean · Change in cells per mm^2
Biopsy Study: Change From Baseline in CD8+ T-cells Tumour Infiltration-density in the Center Tumor Region
Change in cells per mm^2Biopsy Study: Ceralasertib + Durvalumab
On-treatment-183.589 ± 740.398
Off-treatment-85.259 ± 396.091
PrimaryBiopsy Study: Change From Baseline in CD8+ T-cells Tumour Infiltration-density in the Invasive Margin Region

Changes in CD8+ T-cell infiltration of tumours induced by ceralasertib monotherapy was assessed in baseline and off-treatment tumour biopsies As per planned in protocol, this outcome measure was assessed only for biopsy study.

Time frame:
Baseline, and Off-treatment (Cycle 0 Day 15-28) (each cycle is 28 days)
Reported as:
Median · Change in cells per mm^2
Biopsy Study: Change From Baseline in CD8+ T-cells Tumour Infiltration-density in the Invasive Margin Region
Change in cells per mm^2Biopsy Study: Ceralasertib + Durvalumab
Biopsy Study: Change From Baseline in CD8+ T-cells Tumour Infiltration-density in the Invasive Margin RegionNA (-235.53 to -235.53)
SecondaryBiopsy Study: Change From Baseline in Proliferation (Using Ki67+ Marker) of Carcinoma and/or Immune Cells (Including CD8+ T Cells) - Cell Density in Invasive Margin Region

Changes in the proliferation of carcinoma and/or immune cells within tumours induced by ceralasertib monotherapy was assessed. As per planned in protocol, this outcome measure was assessed only for biopsy study.

Time frame:
Baseline, On-treatment (Cycle 0 Day 7); Off-treatment (Cycle 0 Day 15-28) (each cycle is 28 days)
Reported as:
Median · Change in cells per mm2
Biopsy Study: Change From Baseline in Proliferation (Using Ki67+ Marker) of Carcinoma and/or Immune Cells (Including CD8+ T Cells) - Cell Density in Invasive Margin Region
Change in cells per mm2Biopsy Study: Ceralasertib + Durvalumab
CD8+ IHC: Off-treatment (Cycle 0 Day 15-28)NA (-235.53 to -235.53)
Ki67+ IHC: Off-treatment (Cycle 0 Day 15-28)NA (194.39 to 194.39)
SecondaryBiopsy Study: Change From Baseline in Proliferation (Using Ki67+ Marker) of Carcinoma and/or Immune Cells (Including CD8+ T Cells) - Area in Centre Tumour Region

Changes in the proliferation of carcinoma and/or immune cells within tumours induced by ceralasertib monotherapy was assessed. As per planned in protocol, this outcome measure was assessed only for biopsy study.

Time frame:
Baseline, On-treatment (Cycle 0 Day 7); Off-treatment (Cycle 0 Day 15-28) (each cycle is 28 days)
Reported as:
Mean · Percent change
Biopsy Study: Change From Baseline in Proliferation (Using Ki67+ Marker) of Carcinoma and/or Immune Cells (Including CD8+ T Cells) - Area in Centre Tumour Region
Percent changeBiopsy Study: Ceralasertib + Durvalumab
CD8+ cells: On-treatment (Cycle 0 Day 7)-0.976 ± 2.920
CD8+ cells: Off-treatment (Cycle 0 Day 15-28)-0.451 ± 1.357
Ki67+ Cells: On-treatment (Cycle 0 Day 7)-1.953 ± 2.616
Ki67+ Cells: Off-treatment (Cycle 0 Day 15-28)0.754 ± 6.931
SecondaryBiopsy Study: Change From Baseline in Proliferation (Using Ki67+ Marker) of Carcinoma and/or Immune Cells (Including CD8+ T Cells) - Area in Invasive Margin Region

Changes in the proliferation of carcinoma and/or immune cells within tumours induced by ceralasertib monotherapy was assessed. As per planned in protocol, this outcome measure was assessed only for biopsy study.

Time frame:
Baseline, On-treatment (Cycle 0 Day 7); Off-treatment (Cycle 0 Day 15-28) (each cycle is 28 days)
Reported as:
Median · Percent change
Biopsy Study: Change From Baseline in Proliferation (Using Ki67+ Marker) of Carcinoma and/or Immune Cells (Including CD8+ T Cells) - Area in Invasive Margin Region
Percent changeBiopsy Study: Ceralasertib + Durvalumab
CD8+ cells: Off-treatment (Cycle 0 Day 15-28)NA (-0.73 to -0.73)
Ki67+ Cells: Off-treatment (Cycle 0 Day 15-28)NA (1.08 to 1.08)

Adverse events

Collected over From screening (Day -28 to -1) until Safety follow-up (30 days after last dose of Ceralasertib monotherapy or 90 days after last dose of Ceralasertib+Durvalumab combination) or data cut-off (2 years), whichever occurred first. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Main Study: Ceralasertib + Durvalumab43/100 (43%)19/97 (19.6%)86/97 (88.7%)
Main Study: Ceralasertib Monotherapy23/51 (45.1%)5/52 (9.6%)43/52 (82.7%)
Biopsy Study: Ceralasertib + Durvalumab14/41 (34.1%)9/41 (22%)34/41 (82.9%)
Most frequent serious events
Showing 10 of 38
Most frequent serious events
EventMain Study: Ceralasertib + DurvalumabMain Study: Ceralasertib MonotherapyBiopsy Study: Ceralasertib + Durvalumab
PneumoniaInfections and infestations2/970/522/41
AnaemiaBlood and lymphatic system disorders3/971/520/41
SepsisInfections and infestations1/970/521/41
Urinary tract infectionInfections and infestations1/970/521/41
UrosepsisInfections and infestations0/971/521/41
DyspnoeaRespiratory, thoracic and mediastinal disorders2/970/521/41
Arthritis bacterialInfections and infestations0/970/521/41
COVID-19Infections and infestations0/970/521/41
GastroenteritisInfections and infestations0/970/521/41
Gastroenteritis norovirusInfections and infestations0/970/521/41
Most frequent other events
Showing 10 of 43
Most frequent other events
EventMain Study: Ceralasertib + DurvalumabMain Study: Ceralasertib MonotherapyBiopsy Study: Ceralasertib + Durvalumab
NauseaGastrointestinal disorders50/9719/5220/41
AnaemiaBlood and lymphatic system disorders35/979/5215/41
VomitingGastrointestinal disorders21/978/5213/41
FatigueGeneral disorders19/9714/5210/41
Decreased appetiteMetabolism and nutrition disorders20/9712/5211/41
DiarrhoeaGastrointestinal disorders11/976/5211/41
AstheniaGeneral disorders22/9711/528/41
ConstipationGastrointestinal disorders10/971/528/41
PruritusSkin and subcutaneous tissue disorders17/975/520/41
DyspnoeaRespiratory, thoracic and mediastinal disorders3/974/527/41

Baseline characteristics

For main study: Full analysis set (FAS) included all participants who were randomized in the study. For biopsy study: Safety analysis set included all participants who received at least 1 dose of study treatment.

Age, Continuous
Age, Continuous(Years)Main Study: Ceralasertib + DurvalumabMain Study: Ceralasertib MonotherapyBiopsy Study: Ceralasertib + DurvalumabTotal
Mean62.9 ± 13.662.9 ± 12.661.4 ± 11.962.6 ± 13.0
Sex: Female, Male
Sex: Female, Male(Participants)Main Study: Ceralasertib + DurvalumabMain Study: Ceralasertib MonotherapyBiopsy Study: Ceralasertib + DurvalumabTotal
Female42221680
Male582925112
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Main Study: Ceralasertib + DurvalumabMain Study: Ceralasertib MonotherapyBiopsy Study: Ceralasertib + DurvalumabTotal
White793931149
Asian97016
Other2103
Not reported1041024
08

Study locations

66 sites
  • Research Site
    Los Angeles, California 90024, United States
  • Research Site
    Sacramento, California 95816, United States
  • Research Site
    San Francisco, California 94143, United States
  • Research Site
    Tampa, Florida 33612, United States
  • Research Site
    Lutherville-Timonium, Maryland 21093, United States
  • Research Site
    Nashville, Tennessee 37232, United States
  • Research Site
    Darlinghurst, 2010, Australia
  • Research Site
    East Melbourne, 3002, Australia
  • Research Site
    Herston, 4029, Australia
  • Research Site
    Woolloongabba, 4102, Australia
  • Research Site
    Belgium, 1200, Belgium
  • Research Site
    Bruges, 8000, Belgium
  • Research Site
    Ghent, 9000, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Edmonton, Alberta t6G1Z2, Canada
  • Research Site
    Toronto, Ontario M4N 3M5, Canada
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Ste-Foy, Quebec G1V 4G2, Canada
  • Research Site
    Bobigny, 93009, France
  • Research Site
    Boulogne-Billancourt, 92100, France
  • Research Site
    Marseille, 13385, France
  • Research Site
    Paris, 75010, France
  • Research Site
    Pau, 64046, France
  • Research Site
    Pierre-Bénite, 69310, France
  • Research Site
    Poitiers, 86021, France
  • Research Site
    Vandœuvre-lès-Nancy, 54511, France
  • Research Site
    Villejuif, 94805, France
  • Research Site
    Berlin, 10117, Germany
  • Research Site
    Buxtehude, 21614, Germany
  • Research Site
    Heidelberg, 69120, Germany
  • Research Site
    Heilbronn, 74078, Germany
  • Research Site
    Kiel, 24105, Germany
  • Research Site
    Mainz, 55131, Germany
  • Research Site
    München, 80337, Germany
  • Research Site
    Regensburg, 93053, Germany
  • Research Site
    Schwerin, 19049, Germany
  • Research Site
    Tübingen, D-72076, Germany
  • Research Site
    Candiolo, 10060, Italy
  • Research Site
    Milan, 20141, Italy
  • Research Site
    Naples, 80131, Italy
  • Research Site
    Padova, 35128, Italy
  • Research Site
    Perugia, 06156, Italy
  • Research Site
    Roma, 00168, Italy
  • Research Site
    Siena, 53100, Italy
  • Research Site
    Brzozów, 36-200, Poland
  • Research Site
    Gdansk, 80-214, Poland
  • Research Site
    Krakow, 31-115, Poland
  • Research Site
    Lodz, 93-513, Poland
  • Research Site
    Poznan, 60-355, Poland
  • Research Site
    Warsaw, 02-781, Poland
  • Research Site
    Goyang, 410-769, South Korea
  • Research Site
    Seoul, 03722, South Korea
  • Research Site
    Seoul, 05505, South Korea
  • Research Site
    Seoul, 06351, South Korea
  • Research Site
    Barcelona, 08041, Spain
  • Research Site
    Madrid, 28007, Spain
  • Research Site
    Madrid, 28027, Spain
  • Research Site
    Madrid, 28034, Spain
  • Research Site
    Madrid, 28040, Spain
  • Research Site
    Málaga, 29009, Spain
  • Research Site
    Pamplona, 31008, Spain
  • Research Site
    Pozuelo de Alarcón, 28223, Spain
  • Research Site
    Cambridge, CB2 0QQ, United Kingdom
  • Research Site
    Chelsea, SW3 6JJ, United Kingdom
  • Research Site
    Manchester, M20 4BX, United Kingdom
  • Research Site
    Northwood, HA6 2RN, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Apr 2024, 20 months.

Results were first posted in May 2025, 1 year 1 month after primary completion.

Of 106 industry-sponsored phase 2 interventional studies under Melanoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 60. This study's 20 months is below that.

Counting every sponsor, half of 383 studies reached it within 53 months; a quarter within 32 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2021
First posted
Sep 29, 2021
StartActual
Aug 11, 2022
Primary completionActual
Apr 12, 2024
CompletionEst.
Nov 2, 2026
Results first posted
May 21, 2025
Last update
Jul 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05061134
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 29, 2021
Start date
Aug 11, 2022
Primary completion
Apr 12, 2024
Completion
Nov 2, 2026 (estimated)
Results posted
May 21, 2025
Last update
Jul 31, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ceralasertib

Start the discussion